Interim Report 1, The world leader in innovative evidence-based esthetic dental solutions

Size: px

Start display at page:

Download "Interim Report 1, The world leader in innovative evidence-based esthetic dental solutions"

Lorena Horn
6 years ago
Views:

1 Interim Report 1, 2007 The world leader in innovative evidence-based esthetic dental solutions

2 Disclaimer: This presentation contains forward-looking statements that are subject to various risk and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing.

4 Nobel Biocare in 60 Seconds > Number 1 position globally and in all regions > SWX market cap of CHF 11.5 bn > >2100 employees worldwide > The one-stop shop for restorative esthetic dentistry > Leading in science, training and education, innovation > Our focus is the patient and the dental professional our customer The world leader in innovative evidence-based esthetic dental solutions

5 Profit Lines of Income Statement Show All New Record Levels Revenue Gross profit Gross margin EBIT EBIT margin Profit for the period Profit margin Operating Cash Flow Basic earnings p. share Q EUR Q EUR Growth +20%* + 15% 84.2% 83.7% +50bp % 34.0% 34.0% % 26.9% 26.1% +80bp % % *Revenue growth in local currencies

6 Strong Performance track record since 2001 Revenue Growth (%) > More than doubled revenues in five years FY 2001: Euro Mio. FY 2006: Euro Mio. > Outgrowing the market since % 20% 15% 10% 12.4% 19.7% Q107 > Highest EBIT margin in the dental industry EBIT margin % 35% 34.0 % FY 2001: 13.5 % FY 2006: 34.0 % Q1 2007: 34.0 % 30% 25% 20% 15% 20.3% Q107

7 Maintained Record EBIT Margin Despite Significant Higher Social Charges 34.0% +0.5% +1.9% 36.4% 34.0% -2.4% Reported EBIT margin Q1 06 Gross margin Operating expenses EBIT margin Q1 07 Social charges Reported EBIT margin Q1 07

8 Record Net Profit for the quarter EUR 7.1 million contribution to EBIT Net Profit Q1 06 Gross Profit Operating expenses Social Charges Financial result Taxes Net Profit Q1 07 in EUR million

9 Balance Sheet and Cash Flow at a Glance MEUR Inventories in percent of revenue* Current receivables in percent of revenue* Cash Flow from operations in percent of revenue Capital Expenditures in percent of revenue Equity/Asset ratio 31/03/ % 31/03/ % * annualized

10 Strong Operational Cash Flow doubled vs Q Cash available Jan 1 in EUR million Operating activities Investing activites Interest Share buyback Other Financing Activities / Currency impact Cash available Mar 31

11 Operational Highlights Q Global workforce expansion > 115 new employees in Q > 50% new employees since end of : 1328 employees 2006: 1993 employees Trainer and Educator of the Industry > Q ,000 participants in the Group s training programs, > +22% compared to Q Employees Q107 Number of trained (000) Q107 Target 2007

Operational Highlights Q1 2007 State-of-the-art Infrastructure Distribution Center, Venlo (NL) > New

> ISO 13485:2003 certified Youdecide weprovide Shop Online > Shop Online orders for standard

12 Operational Highlights Q State-of-the-art Infrastructure Distribution Center, Venlo (NL) > New state-of-the-art European distribution center opened in Venlo, the Netherlands. > ISO 13485:2003 certified Youdecide weprovide Shop Online > Shop Online orders for standard components increased by more than 50% compared to Q > Together with Procera, 20% of all orders are coming through Shop Online.

13 Operational Highlights Q Reduce lack of Information > FY ,336 editorial articles Editorial articles 1500 > Q editorial articles, 26% more than Q > NobelSmile patient campaign in 34 countries Q1 2007

14 World Market Leader in C&B&I Market Shares in Dental Implant Market > No. 1 position globally Source: Company Reports and Nobel Biocare estimates > No. 1 position in North America, Europe, Asia and Rest of the World > World market leader in C&B&I > Root-to-tooth solutions 9% Zimmer 15% Others 6% Dentsply 37% Nobel Biocare 11% Biomet/3i 22%Straumann

15 Leader in All Regions Q Revenues by Region (MEUR) Revenue Growth by Region (%) Q107 vs. Q106 Asia/Pacific Rest of World % 9.0 5% % North America % 24% 45% 33% 49% % % 18% 12% 0 Europe North America Europe Asia/Pacific ROW

16 Growing the Market

17 6-10% of the Worldwide Population is Fully Edentulous Nearly 50 million fully edentulous people in the western world USA 33 % >65 years Brasil 74 % >65 years United Kingdom (one jaw) 30 % >55 years Germany 25 % >65 years Spain 37 % >65 years Canada 58 % >65 years Italy 19 % >65 years France 16 % >65 years Netherland 64 % >65 years Portugal 70 % >65 years Belgium 41 % >65 years Switzerland 27 % >65 years Sweden 13 % >65 years Source: WHO

18 Huge Untapped Worldwide Market Potential to Serve Fully Edentulous People... and another 36 million people in Asia China 11 % >65 years India 19 % >65 years Japan 20 % >65 years Indonesia 24 % >65 years Vietnam 23 % >65 years Southkorea 22 % >65 years Thailand 16 % >65 years Malaysia 57 % >65 years Hong Kong 20 % >65 years Source: WHO

19 Sustainable Future Growth Potential in the Tooth Replacement Market Estimated 50 bn Market Potential in North America, Europe, Japan > Market penetration in North America, Europe and Japan still around 3% > ~ 50 bn Market Potential North America, Europe, Japan > China, India, Russia, Latin America largely untapped > Sustainable industry growth for coming years of 18 20% p.a. Source: WHO and Nobel Biocare estimates 3% 19% 78% ~ 8 million patients treated with dental implants >240 million people missing one tooth or more (North America, Europe, Japan) ~ 60 million patients treated conventionally

20 Nobel Biocare Grows Faster than the Market Revenue Growth Rates in % > Above market growth in every region > Strong growth in emerging markets Source: MRG and Nobel Biocare estimates Nobel Biocare Market (MRG)* * Based on MRG s overall market - Nobel Biocare excluded

21 Limitations for Growth Patient Lack of information Fear of Pain Affordability Time Allergies Bone quality & quantity Dental professional Lack of information Lack of education Education in Universities

22 and Nobel Biocare has Unique Solutions for all Patient Patient Lack of information NobelSmile Awareness Campaign Fear of pain Graftless Proc. / Minimal Invasive Limitations for Growth Affordability Time Allergies Bone quality & quantity Dental professional Lack of information Lack of education Education in universities Unique Nobel Biocare Solutions Overdenture / All-on-4 /Teeth-in-anhour Immediate Function / NobelGuide Metal Free Solution (ZiUnite) Bone Inductive Implant (BMP-2) Dental professional World Conference / World Tour Training & Education / World Tour University undergraduate programs NobelSmile Campaign & Find a doctor Growing the Market

23 Trendsetter of the Industry with the Highest Number of High Impact Introductions > 1965 First modern dental implant > 1988 Inventor of CAD/CAM in dentistry > 1995 Inventor of modern ceramic materials in dentistry > 1997 Replace tapered implant > 2002 Immediate Function > 2003 NobelPerfect > 2004 NobelDirect NobelRondo Personalized abutments for Straumann, 3i, Zimmer and Lifecore > 2005 NobelGuide Teeth-in-an-Hour Groovy NobelSpeedy / Shorty TiUnite all the way up > 2006 Procera Bridge Alumina Procera Laminate

24 Trendsetter of the Industry with the Highest Number of High Impact Introductions > NobelRondo Press Procera Implant Bridge Zirconia Procera Bridge Zirconia for teeth (for up to 14 units) > Platform shifting QuickTemp Abutment conical Maxillofacial Concept NobelActive Curvy Abutment

25 Overcome Fear of Pain Immediate Function > TiUnite maintains initial stability > TiUnite : Biomaterial with proven osteoconductivity > TiUnite : Carrier for bioactive agents. No grafting and no membranes needed > 75 Studies* on Immediate Function > 5 year data with excellent results Only Surface with a Proven Clinical Protocol for Immediate Function TiUnite Machined Surface 0 1 Week 1 Month 2 Months 3 Months 6 Months Results of resonance frequency analyses show that the high initial stability achieved with TiUnite is maintained at a high level throughout the healing phase. Glauser et al. Applied Osseointegration Research 2001;2: *Source: Medline

26 Reduce Limitations of Time > NobelGuide a system for complete oral rehabilitation > FDA approved since 2004 > One surgical visit required with NobelGuide > NobelGuide is a proven concept with full flexibility 3-4 Visits with NobelGuide Treatment Planning Surgical Procedure Temporary / Final Prosthetic Solution Final Prosthetic Solutions 10 Visits Convential Approach Treatment Planning Surgical Procedure Relining Remove Stitches Abutment Connection Temporary Prosthetic Solution Soft-tissue Control Impression Try in of Prosthesis Final Prosthetic Solutions

Reduce Limitation Lack of Patient Information www.nobelsmile.

NobelSmile website: 250,000 visitors in 2006 > Direct patient dialogue to inform on today s treatment

27 Reduce Limitation Lack of Patient Information > NobelSmile Campaign in 34 countries and 20 languages with patient feature: > Search for a doctor > NobelSmile website: 250,000 visitors in 2006 > Direct patient dialogue to inform on today s treatment solutions > National patient information events > Information packages for patients > Collaborations with spokespersons Patient Seminar on World Tour in Dresden 2006

28 Previous Nobel Biocare World Conferences > ,600 participants 62 speakers 84 presentations > ,000 participants 176 speakers 7 live sessions 40 translators 74 different nationalities attending

29 Nobel Biocare World Conference 2007 > , 000 participants 340 speakers from 34 countries 35 live sessions 2,143 presentations 313 scientific posters 91 nationalities attending

30 All Nobel Biocare Solutions are Evidence Based > Over 1800 peer reviewed scientific publications > Strongest scientific database in the industry > More than 50% of all scientific studies come from Nobel Biocare > >600 renowned scientists and dental practitioners > All products launched globally with FDA approval > 60 university research collaborations worldwide 100 Nobel Biocare has more Studies on Immediate Function than the other Companies Together NB ITI 3i Astra Others MedLine database, April 2007

osseointegrated reconstructions > iadh - International organization for the treatment of disabled patients >

31 Nobel Biocare s Strong Commitment to Social Responsibility > SOS-Children s Villages, Kiev, Ukraine > P-I Brånemark Institute, Bauru, Brazil Donation run institute for treatment for needy patients requiring osseointegrated reconstructions > iadh - International organization for the treatment of disabled patients > Cleft-Children, organization for the treatment of children with severe cleft lip and palate P-I Brånemark Institute, Bauru

32 Outlook 2007 Revenue Growth* 23-25% EBIT margin 34-35% *in local currency

Nobel Biocare Group Full Year Report 2005

Nobel Biocare Group Full Year Report 2005 Zurich, Switzerland 9 February 2006 Nobel Biocare again outpaces market with record revenue growth of 25% and an EBIT margin of 33.5% in 2005 Revenue for the full